BioLeaders Edging Ahead In Dysplasia Therapeutics
This article was originally published in PharmAsia News
Executive Summary
South Korea’s BioLeaders is making solid progress with its pipeline projects for dysplasia, preparing to begin a global Phase III trial with an oral immunotherapy, and adding a new domestic partner to a 2013 global licensing deal for an oral therapeutic vaccine.